TTVR强劲的覆盖范围和证据开发(CED)研究 (STRONG)
经导管三尖瓣置换(TTVR)的严重TR持续证据产生(强)覆盖范围的患者,证据开发(CED)(CED)
This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
研究概览
详细说明
This is a retrospective, non-randomized cohort study measuring 2-year effectiveness of the EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) system in the real-world.
This study will retrospectively evaluate EVOQUE treated patients in the STS/ACC TVT Registry who have at least severe Tricuspid Regurgitation and can be deterministically linked with Medicare data.
This group will be compared to Medicare eligible and EVOQUE eligible patients evaluated in a standard of care setting from a commercial claims database linked with electronic health records.
We will evaluate the primary outcome measure in various subgroups.
There will be continued access enrollment after the primary completion date.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:TMTT GHER
- 电话号码:949-250-3849
- 邮箱:TMTT_GHER_EVIDENCE@edwards.com
学习地点
-
-
California
-
Irvine、California、美国、92614
- 招聘中
- Edwards Lifesciences
-
接触:
- TMTT GHER
- 邮箱:TMTT_GHER_EVIDENCE@edwards.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Medicare eligible real-world patients with severe, symptomatic tricuspid regurgitation
描述
Inclusion Criteria:
Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation
Exclusion Criteria:
Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
EVOQUE treated
Medicare patients with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement with the EVOQUE device and is identified in the TVT Registry |
This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team. |
|
EVOQUE eligible
Medicare eligible patients with severe, symptomatic Tricuspid Regurgitation that are identifiable in a commercial claims database linked with electronic health records. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite (All-Cause Death or Heart Failure Hospitalization)
大体时间:2 years
|
Time to death or heart failure hospitalization after time zero |
2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.